How do I set a price alert for INO?

To set a INO price alert on Stock Alarm Pro, navigate to the INO quote page, select "Set Alert," choose your trigger type (price target, % move, RSI level, MACD, or volume breakout), and set your delivery channel. Stock Alarm Pro supports instant push notifications, SMS, and automated phone call alerts.

Can I get phone call alerts for INO?

Yes. Stock Alarm Pro provides real-time automated phone call alerts for INO. Phone call alerts ensure you are immediately awakened or interrupted during critical volatility events, overnight earnings moves, or strict stop-loss levels when silent push notifications might be overlooked.

What types of alerts can I set for INO?

Stock Alarm Pro supports over 125 trigger types for INO: price target alerts (above/below target), intraday percentage moves, RSI overbought/oversold levels, 50-day and 200-day moving average crossovers (golden cross / death cross), relative volume (RVOL) spikes, confirmed earnings date releases, and SEC Form-4 insider transaction filings.

How quickly will I be notified about INO price changes?

INO alerts are evaluated continuously in real-time against live market telemetry. Notifications are dispatched within sub-second latency via push notifications, SMS, or phone calls as soon as your trigger condition is met across regular, pre-market, and after-hours trading sessions.

Is Stock Alarm Pro free to use for INO alerts?

Yes, Stock Alarm Pro offers a free tier that includes 3 active price alerts for INO and other stocks. Full Pro membership is $20/month or $168/year with a 7-day free trial, unlocking unlimited alerts, phone call delivery, SMS, all 125+ technical indicators, institutional screeners, and real-time market telemetry across web, iOS, and Android.

INO Company Intelligence - Business Model, Drivers & Risks

Inovio Pharmaceuticals, Inc.(INO)

$0.99—

WatchlistChart

Inovio Pharmaceuticals, Inc.(INO)

NASDAQAbout this dataData status

$0.99—

WatchlistChart Studio

INO(INO)

INO

Inovio Pharmaceuticals, Inc. focuses on developing DNA-based immunotherapies and vaccines for infectious diseases and cancer. Its lead product candidates include INO-4800, a COVID-19 vaccine, and VGX-3100, a treatment for cervical dysplasia, which are positioned in competitive markets with significant unmet medical needs.

HealthcareBiotechnologylow - Inovio has high fixed costs associated with R&D and clinical trials, with no current revenue to offset these expenses.

Business Overview

01Product sales from clinical trials (0% as currently no revenue)

02Collaborative agreements with pharmaceutical companies (0% as currently no revenue)

03Grants and funding for research (0% as currently no revenue)

Inovio's business model is primarily based on the development of innovative DNA-based therapies, which it seeks to monetize through partnerships, licensing agreements, and potential future product sales. The company has a competitive advantage in its proprietary platform technology for delivering DNA vaccines, which has shown promise in various clinical trials.

What Moves the Stock

Clinical trial results for INO-4800 and VGX-3100

Partnership announcements with larger pharmaceutical companies

Regulatory approvals from the FDA or other health authorities

Market sentiment regarding the biotechnology sector

Watch on Earnings

Progress in clinical trialsPartnership and collaboration announcementsCash burn rate and funding needs

Risk Factors

Regulatory changes impacting drug approval processes

Technological disruption from competing vaccine platforms

Emergence of alternative therapies for COVID-19 and cervical dysplasia

Increased competition from established pharmaceutical companies with more resources

High debt levels relative to market cap and revenue generation

Liquidity risks due to negative cash flow

StructuralCompetitiveBalance Sheet

Macro Sensitivity

Economic Cycle

low - As a biotech firm, Inovio's performance is less directly tied to the economic cycle compared to consumer discretionary sectors.

Interest Rates

Higher interest rates could increase the cost of capital for Inovio, impacting its ability to fund ongoing R&D and clinical trials, which are critical for its growth.

Credit

minimal - The company does not rely heavily on credit for operations, but its high debt/equity ratio indicates potential vulnerability to credit conditions.

Live Conditions

Dow Jones FuturesRussell 2000 FuturesS&P 500 Futures